AM095 sodium salt 1345614-59-6

簡要描述：AM095 sodium salt 1345614-59-6
AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 _mu_M for recombinant human or mouse LPA1 respectively.

產(chǎn)品型號：abs47027883
廠商性質(zhì)：生產(chǎn)廠家
更新時間：2026-01-05
訪問量：682

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

生化試劑

其它生化試劑植物提取物碳水化合物生物緩沖劑熒光探針與染料表面活性劑酶&輔酶&酶底物蛋白質(zhì)組學(xué) 動植物激素小分子化合物生化檢測試劑盒逆行示蹤劑抗生素核苷&核苷酸多肽

查看全部

相關(guān)文章

詳細介紹

品牌	absin	CAS	1345614-59-6
分子式	C27H23N2NaO5	純度	98%
分子量	478.47	貨號	abs47027883
規(guī)格	10mg	供貨周期	現(xiàn)貨
主要用途	is a potent LPA1 receptor	應(yīng)用領(lǐng)域	化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合

AM095 sodium salt 1345614-59-6

產(chǎn)品描述
描述	AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 _mu_M for recombinant human or mouse LPA1 respectively.
純度	98%
儲存/保存方法	Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
基本信息
可溶性/溶解性	DMSO : ≥ 170 mg/mL (355.30 mM)
生物活性
靶點	LPL Receptor
In vitro(體外研究)	AM095 is a potent LPA1 receptor antagonist because it inhibits GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 μM, respectively. AM095 inhibits LPA-driven chemotaxis of CHO cells overexpressing mouse LPA1 (IC50=778 nM) and human A2058 melanoma cells (IC50=233 nM). The IC50 of AM095 in the human LPA1 GTPγS binding assay is comparable with that of our previously published compound AM966 (IC50=0.98±0.17 μM) and the Debio-0719 compound (IC50=0.60±0.04 μM). AM095 inhibits the LPA-induced calcium flux of CHO cells stably transfected with human or mouse LPA1. The IC50 for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHO cells is 0.025 and 0.023 μM, respectively.
In vivo(體內(nèi)研究)	AM095 has high oral bioavailability and a moderate half-life and is well tolerated at the doses tested in rats and dogs after oral and intravenous dosing. After oral (10 mg/kg) dosing in rats, AM095 plasma concentrations peaked at 2 h with a Cmax of 41 μM, thereafter decreasing to 10 nM by 24 h. After intravenous (2 mg/kg) dosing, a Cmax of 12 μM is observed within 15 min, which also decreased to approximately 10 nM by 24 h, yielding a t1/2 of 1.79 h. In dogs, a single oral dose of 5 mg/kg yielded a peak plasma concentration of 21 μM within 15 min of dosing, which then decreased to 10 nM by 24 h. In contrast, an intravenous dose of 2 mg/kg resulted in a Cmax of 11 μM within 15 min and decreased to 15 nM by 8 h, yielding a t1/2 of 1.5 h.
參考文獻
參考文獻	1. Swaney JS,et al. Journal of Pharmacology and Experimental Therapeutics (2011), 336(3), 693-700. 2. Castelino FV, et al. Arthritis & Rheumatism (2011), 63(5), 1405-1415.

研究領(lǐng)域
研究領(lǐng)域	Immunology Drug DiscoverySmall Molecule DrugLead Compound Discovery

AM095 sodium salt 1345614-59-6溫馨提示：本產(chǎn)品僅作科研實驗使用，不支持臨床等研究

產(chǎn)品咨詢

留言框

產(chǎn)品：
您的單位：
您的姓名：
聯(lián)系電話：
常用郵箱：
省份：
詳細地址：
補充說明：
驗證碼：

請輸入計算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

上一篇：abs47027881Mertansine 139504-50-0
下一篇：abs47027884TP0903 1341200-45-0

AM095 sodium salt 1345614-59-6

留言框

產(chǎn)品：

您的單位：

您的姓名：

聯(lián)系電話：

常用郵箱：

省份：

詳細地址：

補充說明：

驗證碼：